EMERGING BIOSIMILARS IN ONCOLOGY: A REVIEW
DOI:
https://doi.org/10.22159/ajpcr.2018.v11s4.31720Keywords:
Biosimilars, Inner biological molecules, Food and drug aministration, DNA recombinant protein, OncologistAbstract
Biosimilars are the biological medicinal products that produce the therapeutic effects in the human body similar to that of inner biological molecule. Biopharmaceuticals consist of nucleic acids, amino acids, polysaccharides, or combination of all compounds. In India, the steps have been taken to manufacture biosimilars with the lowest cost and least side effects. Globally, India is one of the major developing countries in manufacturing and marketing of biosimilars. The application of biosimilar was rapidly growing in treating various disorders such as cancer, inflammatory disease, and cardiovascular diseases. For the approval of biosimilars, in vitro studies become the necessity for representing comparison to a standard biological in terms of quality for experimental studies indicating similar pharmacokinetics, efficacy, safety, and immunogenicity. Huminsulin was the first DNA-recombinant protein accepted by the US Food and Drug Administration (FDA) in 1982. As currently there are no FDA-approved biosimilars for treating breast cancer, many biologic antibodies are under investigation.
Downloads
References
Blanchard A, D’Iorio H, Ford R. What You Need to Know to Succeed. Canada: Key Trends in Canada’s Biotech Industry. Insights, Spring; 2010.
Fernandes GS, Sternberg C, Lopes G, Chammas R, Gifoni MC, Gil RA, et al. The use of biosimilar medicines in oncology – Position statement of the Brazilian society of clinical oncology (SBOC). Brazil J Med Biol Res 2018;51:e7214.
van Aerts LA, De Smet K, Reichmann G, van der Laan JW, Schneider CK. Biosimilars entering the clinic without animal studies. A paradigm shift in the european union. MAbs 2014;6:1155-62.
Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002576/human_med_001682.jsp&mid=WC0b01ac058001d124.
Danese S, Gomollon F, Governing Board and Operational Board of ECCO. ECCO position statement: The use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). J Crohns Colitis 2013;7:586-9.
Grabowski D, Henderson B, Lam D, Keystone EC, Thorne C, Jamal S, et al. Attitudes towards subsequent entry biologics/biosimilars: A survey of Canadian rheumatologists. Clin Rheumatol 2015;34:1427-33.
Jacobs I, Petersel D, Shane LG, Ng CK, Kirchhoff C, Finch G, et al. Monoclonal antibody and fusion protein biosimilars across therapeutic areas: A Systematic review of published evidence. BioDrugs 2016;30:489-523.
Berghout A. Clinical programs in the development of similar biotherapeutic products: Rationale and general principles. Biologicals
;39:293-6
Malhotra H. Biosimilars and non-innovator biotherapeutics in India: An overview of the current situation. Biologicals 2011;39:321-4.
Bui LA, Taylor C. Developing clinical trials for biosimilars. Semin Oncol 2014;41 Suppl 1:S15-25.
Available from: http://www.pharmpro.com/news/2016/05/top-25-biosimilar-drug-manufacturers.
Available from: https://www.visiongain.com/Report/1627/Pharma-Leader-Series-25-Top-Biosimilar-Drug-Manufacturers-2016-2026.
Jayaraman K. India’s cipla sets sights on avastin, herceptin and enbrel. Nat Biotechnol 2010;28:883-4.
Available from: https://www.pharmafocusasia.com/research_development/blind-comparative-study.html.
Available from: http://www.biospectrumindia.com/biospecindia/news/155886/india-biologics-trail.
US Food and Drug Administration: Guidance for Industry: Scientific Considerations in Demonstrating Biosimilarity to a Reference Product.
Feagan BG, Choquette D, Ghosh S, Gladman DD, Ho V, Meibohm B, et al. The challenge of indication extrapolation for infliximab biosimilars. Biologicals 2014;42:177-83.
Available from: https://www.ema.europa.eu/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-monoclonal-antibodies-non-clinical_en.
Available from: http://www.cdsco.nic.in/writereaddata/Proposed%20Guidelines%20for%20Similar%20Biologic%202016.
Kumar R, Singh J. Biosimilar drugs: Current status. Int J Appl Basic Med Res 2014;4:63-6.
Available from: http://www.gabionline.net/Biosimilars/General/Similar-biologics-approved-and-marketed-in-India.
Available from: https://www.issuu.com/uicc.org/docs/wcls2014-economics-of-cancer-final.
Available from: https://www.lexology.com/library/detail.aspx?g=f495c4ce-c417-4e0b-804a-e86fe93569b0.
Ward E, Halpern M, Schrag N, Cokkinides V, DeSantis C, Bandi P, et al. Association of insurance with cancer care utilization and outcomes. CA Cancer J Clin 2008;58:9-31.
Neumann PJ, Sandberg EA, Bell CM, Stone PW, Chapman RH. Are pharmaceuticals cost-effective? A review of the evidence. Health Aff (Millwood) 2000;19:92-109.
Stork WR. Therapeutic monoclonal antibodies- past, present, future. In: An Z, editor. Therapeutic Monoclonal Antibodies-from Bench to Clinic. New York: John Wiley & Sons; 2009. p. 4-50.
Kamaraj R, Manju M. Biosimilar current status in India. Asian J Pharm Clin Res 2017;10:25-8.
Kinch MS. An overview of FDA-approved biologics medicines. Drug Discov Today 2015;20:393-8.
Roger SD. Biosimilars: How similar or dissimilar are they? Nephrology 2006;11:341-6.
Smith A, Manoli H, Jaw S, Frutoz K, Epstein AL, Khawli LA, et al. Unraveling the effect of immunogenicity on the PK/PD, efficacy, and safety of therapeutic proteins. J Immunol Res 2016;2016:2342187.
Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002;346:469 75.
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
Available from: http://www.cancer.gov/about-cancer/treatment/drugs/fda-trastuzumab.
Available from: http://www.gene.com/media/product-information/herceptin-development- timeline.
GaBI Journal Editor. Patent expiry dates for biologicals: 2016 update. Generics Biosimilars Initiat J 2017;6:27-30.
Available from: http://www.business-standard.com/article/companies/worlds 1st-biosimilar-drug-for-breast-cancer.
Rugo HS, Barve A, Waller CF, Hernandez-Bronchud M, Herson J, Yuan J, et al. Effect of a proposed trastuzumab biosimilar compared with trastuzumab on overall response rate in patients with ERBB2 (HER2)-positive metastatic breast cancer: A Randomized clinical trial. JAMA 2017;317:37-47.
Rugo HS, Barve A, Waller CF, Hernandez-Bronchud M, Herson J, Yuan J, et al. Heritage, a phase III safety and efficacy trial of the proposed trastuzumab biosimilar, Myl-1401O vstrastuzumab. Ann Oncol 2016;27 Suppl 6:LBA16.
Rugo HS, Linton KM, Cervi P, Rosenberg JA, Jacobs I. A clinician’s guide to biosimilars in oncology. Cancer Treat Rev 2016;46:73-9.
Available from: http://www.newsroom.mylan.com/2016-11-08-Mylan-and-Biocon-Announce-U-S-FDA-Submission-for-Proposed-Biosimilar-Trastuzumab.
Lammers PE, Dank M, Masetti R, Abbas R, Hilton F, Coppola J, et al. Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer. Br J Cancer 2018;119:266-73.
Camacho LH. Current status of biosimilars in oncology. Drugs 2017;77:985-97.
Malipatil NB, Haridas K, Prithvi SD. An overview of biosimilars. Asian J Pharm Clin Res 2015;8:23-7.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
